Objective: This study aimed to illustrate the techniques of unilateral biportal endoscopic transforaminal lumbar interbody fusion (UBE-TLIF) using double cages and compare surgical outcomes with those using a single cage. Methods: We retrospectively analyzed 62 patients who underwent single-level UBE-TLIF using 3-dimensional (3D)-printed titanium cages (29 with a single cage and 33 with double cages). Radiological parameters, including Bridwell fusion and subsidence grading, were assessed via x-ray and computed tomography at 6 months and 1 year. Clinical outcomes were measured using the visual analogue scale (VAS) for lower back and leg pain, as well as the Oswestry Disability Index (ODI). Results: At the 6-month follow-up, the overall fusion rate (grades I + II) was significantly higher in the double-cage group (86.2% vs. 100%, p=0.04); however, no significant difference was noted at the 1-year follow-up (89.6% vs. 100%). The double-cage group showed lower cage subsidence rates at both follow-ups (3% vs. 31%, p=0.01; 12.1% vs. 38%, p=0.03). The double-cage group exhibited significantly greater improvements in leg pain (VAS: 7.6 to 1.7 vs. 7.2 to 1.4, p=0.03) and ODI (28.6 to 10.8 vs. 28.3 to 9.4, p=0.01) at 1 year. Conclusion UBE-TLIF with 3D-printed titanium cages achieved a favorable fusion rate at the 1-year follow-up, regardless of whether single or double cages were used. However, double cages accelerated fusion at the 6-month follow-up and significantly reduced cage subsidence at both the 6-month and 1-year follow-ups. These benefits contributed to improved VAS scores for leg pain and ODI at the final follow-up.

Objective: Endovascular coil embolization is the primary treatment modality for intracranial aneurysms. However, its long-term durability remains of concern, with a considerable proportion of cases requiring aneurysm reopening and retreatment. Therefore, establishing optimal follow-up imaging protocols is necessary to ensure a durable occlusion. This study aimed to develop guidelines for follow-up imaging strategies after endovascular treatment of intracranial aneurysms. Methods: A committee comprising members of the Korean Neuroendovascular Society and other relevant societies was formed. A literature review and analyses of the major published guidelines were conducted to gather evidence. A panel of 40 experts convened to achieve a consensus on the recommendations using the modified Delphi method. Results: The panel members reached the following consensus: 1. Schedule the initial follow-up imaging within 3-6 months of treatment. 2. Noninvasive imaging modalities, such as three-dimensional time-of-flight magnetic resonance angiography (MRA) or contrast-enhanced MRA, are alternatives to digital subtraction angiography (DSA) during the first follow-up. 3. Schedule mid-term follow-up imaging at 1, 2, 4, and 6 years after the initial treatment. 4. If noninvasive imaging reveals unstable changes in the treated aneurysms, DSA should be considered. 5. Consider late-term follow-up imaging every 3–5 years for lifelong monitoring of patients with unstable changes or at high risk of recurrence. Conclusions The guidelines aim to provide physicians with the information to make informed decisions and provide patients with high-quality care. However, owing to a lack of specific recommendations and scientific data, these guidelines are based on expert consensus and should be considered in conjunction with individual patient characteristics and circumstances.

Objective: This study compared the clinical and radiological outcomes of uniportal endoscopic and biportal endoscopic transforaminal lumbar interbody fusion (TLIF) for lumbar degenerative disease during the early learning stage of the technique. Methods: We retrospectively analyzed patients who underwent uniportal endoscopic TLIF (n=15) and biportal endoscopic TLIF (n=19) between January and October 2021 during the first year of adoption of these techniques. Radiological parameters, including Bridewell fusion and subsidence grading, were evaluated by x-ray and computed tomography (CT) at 3-month, 6-month, and 1-year follow-up visits. Clinical outcomes were evaluated using the visual analogue scale (VAS) and the Oswestry Disability Index (ODI). Results: Uniportal endoscopic TLIF showed significantly higher frequencies of intraoperative endplate injuries (uniportal [20%] vs. biportal [0%], p=0.01) and 1-year cage subsidence (uniportal [60%] vs. biportal [26.3%], p=0.04) than biportal endoscopic TLIF. The 1-year fusion rates did not differ significantly between the 2 surgical groups (uniportal [93.3%] vs. biportal [89.5%], p=0.37). Neural complications such as postoperative dysesthesia and dural tears occurred in uniportal endoscopic TLIF. There were no significant differences in the VAS for back and leg pain or ODI. Conclusion Complete endplate preparation under endoscopic guidance improved interbody fusion, and this procedure may be feasible in the early learning stage, regardless of the type of endoscope. Both endoscopic TLIF techniques achieved good clinical outcomes and fusion rates. However, unskilled use of the cage guide device caused endplate breakage and neural injury during uniportal endoscopic cage insertion. Uniportal endoscopic TLIF may require more experience for appropriate cage insertion.

Objective: Biportal endoscopic surgery was developed to treat degenerative pathologies that cause myelopathy. Thoracic disc herniation accelerates myelopathy at the level of thoracic stenosis caused by ossification of the ligamentum flavum (OLF). This study describes a feasible surgical technique for the biportal endoscopic posterior approach for removing the thoracic OLF and herniated disc that cause thoracic myelopathy. Methods: Bilateral laminar thinning was performed while preserving the midline and contralateral bony structures. The thoracic OLF was thinned and cut at the bony drilled edge using a diamond drill. The OLF was elevated and removed using an en bloc technique after epidural dissection. The herniated disc was removed through the space created after medial facetectomy. All the procedures were performed without neural injury. Results: Postoperatively, the neurological symptoms of thoracic myelopathy improved, as did the upper back and chest wall pain. Conclusion We successfully treated double-crushing lesions of the thoracic herniated disc and OLF using biportal endoscopy. In biportal endoscopic surgery, drills and instruments can be smoothly used in the narrow spinal canal of the upper thoracic vertebrae. The biportal endoscopic posterior thoracic approach may be an attractive surgical option for treating thoracic myelopathy caused by combined degenerative pathologies.

Purpose: Although osimertinib is the standard-of-care treatment of epidermal growth factor receptor (EGFR) T790M mutation–positive non–small cell lung cancer, real-world evidence on the efficacy of osimertinib is not enough to reflect the complexity of the entire course of treatment. Herein, we report on the use of osimertinib in patients with EGFR T790M mutation–positive non–small cell lung cancer who had previously received EGFR tyrosine kinase inhibitor (TKI) treatment in Korea. Materials and Methods: Patients with confirmed EGFR T790M after disease progression of prior EGFR-TKI were enrolled and administered osimertinib 80 mg daily. The primary effectiveness outcome was progression-free survival, with time-to-treatment discontinuation, treatment and adverse effects leading to treatment discontinuation, and overall survival being the secondary endpoints. Results: A total of 558 individuals were enrolled, and 55.2% had investigator-assessed responses. The median progression-free survival was 14.2 months (95% confidence interval [CI], 13.0 to 16.4), and the median time-to-treatment discontinuation was 15.0 months (95% CI, 14.1 to 15.9). The median overall survival was 36.7 months (95% CI, 30.9 to not reached). The benefit with osimertinib was consistent regardless of the age, sex, smoking history, and primary EGFR mutation subtype. However, hepatic metastases at the time of diagnosis, the presence of plasma EGFR T790M, and the shorter duration of prior EGFR-TKI treatment were poor predictors of osimertinib treatment. Ten patients (1.8%), including three with pneumonitis, had to discontinue osimertinib due to severe adverse effects. Conclusion Osimertinib demonstrated its clinical effectiveness and survival benefit for EGFR T790M mutation–positive in Korean patients with no new safety signals.

Objective: : Stent-assisted coil embolization (SAC) has been increasingly used to treat various types of intracranial aneurysms. Delayed thromboembolic complications are major concerns regarding this procedure, so dual antiplatelet therapy with aspirin and clopidogrel is needed. However, clinicians vary the duration of dual antiplatelet therapy after SAC, and no randomized study has been performed. This study aims to compare the safety and efficacy of long-term (12 months) dual antiplatelet therapy and shortterm dual antiplatelet therapy (6 months) after SAC for patients with unruptured intracranial aneurysms (UIAs). Methods: : This is a prospective, randomized and multicenter trial to investigate the optimal duration of dual antiplatelet therapy after SAC in patients with UIAs. Subjects will receive dual antiplatelet therapy for 6 months (short-term group) or 12 months (longterm group) after SAC. The primary endpoint is the assessment of thromboembolic complications between 1 and 18 months after SAC. We will enroll 528 subjects (264 subjects in each group) and perform 1 : 1 randomization. This study will involve 14 topperforming, high-volume Korean institutions specializing in coil embolization. Results: : The trial will begin enrollment in 2022, and clinical data will be available after enrollment and follow-up. Conclusion : This article describes that the aim of this prospective randomized multicenter trial is to compare the effect of short-term (6 months) and long-term (12 months) dual antiplatelet therapy on UIAs in patients undergoing SAC, and to find the optimal duration.

PURPOSE: To understand awareness, attitude and knowledge levels of muscle health of adults over 18 years old. METHODS: This study was a cross-sectional study using questionnaires. A total of 401 questionnaires were included for final analysis. Mean and standard deviation of the continuous variables were analyzed and frequency analysis of categorical variables was performed. To identify differences according to general characteristics, t-test was used. RESULTS: Awareness scores about the importance of muscle health and exercises were 8.3 and 13.0, respectively. Attitude score and knowledge score were 12.4 and 15.0, respectively. There were differences in attitude toward muscle health according to gender, age, physical activity, and diet habits. However, there was no difference in attitude toward muscle health according to educational level, smoking, drinking, or sleeping. CONCLUSION: It is necessary to seek a strategy to improve awareness and attitude toward muscle health based on knowledge, not merely to raise knowledge level about muscle health. Since nurses play a central role in health promotion and disease prevention, they should also play an important role in strategic development and application of intervention.
Adult ; Cross-Sectional Studies ; Drinking ; Exercise ; Food Habits ; Health Promotion ; Humans ; Motor Activity ; Muscles ; Smoke ; Smoking